Photo of David James Pinato taken from www.imperial.nhs.uk
Apr 10, 2024, 09:52
David Pinato: Immunotherapy might become a novel standard of care in intermediate-stage HCC
David Pinato, Director of Developmental Cancer Therapeutics at Imperial College London, shared on LinkedIn:
“Immunotherapy might become a novel standard of care in intermediate-stage HCC.
PETAL is the first study to focus on mechanisms of synergy between TACE and PD-1 inhibition at Imperial College London.”
Proceed to the article.
Source: David Pinato/LinkedIn
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Mar 26, 2025, 16:43
Mar 26, 2025, 16:35
Mar 26, 2025, 15:47
Mar 26, 2025, 15:07
Mar 26, 2025, 14:53
Mar 26, 2025, 14:43
Mar 26, 2025, 14:26